Navigation Links
Reduced Doses of Medication Beneficial to Preschoolers with ADHD

An exhaustive study, the first of its kind, designed to measure the safety and efficacy of treating preschoolers who suffer attention deficit/hyperactivity disorder// (ADHD) with methylphenidate (Ritalin), has revealed that reduced doses of this medication is beneficial and doesn’t cause harm. The study also revealed that it is important to closely observe preschoolers as they are more sensitive than older children to the side effects of medication.

The 70-week, six-site study was funded by the National Institutes of Health's National Institute of Mental Health (NIMH) and was described in several articles in the November 2006 issue of the Journal of the American Academy of Child and Adolescent Psychiatry.

"The Preschool ADHD Treatment Study, or PATS, provides us with the best information to date about treating very young children diagnosed with ADHD," said NIMH Director Thomas R. Insel, MD. "The results show that preschoolers may benefit from low doses of medication when it is closely monitored, but the positive effects are less evident and side-effects are somewhat greater than previous reports in older children."

Methylphenidate is the most commonly prescribed medication to treat children diagnosed with ADHD. But its use for children younger than 6 years has not been approved by the Food and Drug Administration. And until PATS, very few studies--and no large-scale ones--have been conducted to collect reliable, consistent data to help guide practitioners treating preschoolers with ADHD.

The 303 preschoolers enrolled in the study ranged in age from 3 to 5 years. The children and their parents participated in a pre-trial, 10-week behavioral therapy and training course. Only those children with the most extreme ADHD symptoms who did not improve after the behavioral therapy course and whose parents agreed to have them treated with medication were included in the medication study. In the first part of the medication study, the children took a range of doses from a very low amount of 3.75 mg daily of methylphenidate, administered in three equal doses, up to 22.5 mg/day. By comparison, doses for school-aged children usually range from 15 to 50 mg total daily.

The study then compared the effectiveness of methylphenidate to placebo. It found that the children taking methylphenidate had a more marked reduction of their ADHD symptoms compared to children taking a placebo, and that different children responded best to different doses.

"The best dose to reduce ADHD symptoms varied substantially among the children, but the average across the whole group was as low as 14 mg per day," said lead author Laurence Greenhill, M.D., of Columbia University/New York State Psychiatric Institute. "Preschoolers with ADHD may need only a low dose of methylphenidate initially, but they may need to take a higher dose later on to maintain the drug's effectiveness."

To ensure the safety of the very young children involved, the study was governed by a strict set of ethical standards and additional review boards. The children's health was monitored carefully and repeatedly throughout the study's duration. Their parents were repeatedly consulted for consent prior to every step of the program. The researchers also reviewed the teacher ratings of the children who attended preschool at various stages in the study.

Similar to 1999 results found in NIMH's Multimodal Treatment Study of Children with ADHD (MTA study), and other studies on school-aged children, the medication did appear to slow the preschoolers' growth rates. Throughout the duration of the study, the children grew about half an inch less in height and weighed about 3 pounds less than expected, based on average growth rates established prior to the study.

Currently, no data exist that track long-term growth rate changes among preschoolers with ADHD who are medicated with methylphenidate. However, a five-year-long follow-up study is underway to track the children's physical, cognitive, and behavioral development, as well as health care services the family is using to care for the child. Those data will be available in two to three years.

Finally, 89 percent of the children tolerated the drug well, but 11 percent--about 1 in 10 children--had to drop out of the study as a result of intolerable side effects. For example, while some children lost weight, weight loss of 10 percent or more of the child's baseline weight was considered a severe enough side effect for the investigators to discontinue the medication. Other side effects included insomnia, loss of appetite, mood disturbances such as feeling nervous or worried, and skin-picking behaviors. Despite concerns that stimulants may increase blood pressure or pulse, any changes seen in the children's blood pressure or pulse were minimal.

"The study shows that preschoolers with severe ADHD symptoms can benefit from the medication, but doctors should weigh that benefit against the potential for these very young children to be more sensitive than older children to the medication's side effects, and monitor use closely," concluded Dr. Greenhill



Source-Eurekalert
'"/>




Related medicine news :

1. Reduced POD linked to fatal asthma attacks
2. Reduced fertility in men who mountain bike
3. Reduced Fatigue Boosts Mental Health
4. Rejection Rate for Liver Transplants Patient Reduced
5. Calcium-Vitamin D Combo For Reduced Fracture Risk
6. Heart Disease In Women Can Be Reduced By Eating Grapes
7. Cholesterol; Can Be Reduced By Sunflower Seeds, and Pistachios
8. Snoring To Be Reduced By New Device Called True Sleep
9. Infectious Diseases Reduced in China
10. Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy
11. Breast Cancer Treatment Reduced From Six Weeks To Five Days.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Two director-level ... as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes ... workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... or needing intervention to walk, the demand for a sustainable product to aid in ... this void and aid in the recovery of individuals with hemiplegia due to stroke. ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... with Mediaplanet to help educate the many who are unaware of the plight ... to aphasia will run within the “Stroke Awareness” campaign. , The link between ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... ... 2016 , ... Despite last week’s media reports hinting at a June rate ... until March 2017 for an interest rate increase, according to Rajeev Dhawan of the ... “The Federal Open Market Committee (FOMC) dot charts are of interest to the press ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 According ... of hypertension is driving ambulatory blood pressure monitoring system ... elasticity and their ability to respond to different pressure ... condition can lead to various cardiovascular disorders such as ... disease. These diseases are growing in prevalence each year. ...
(Date:5/27/2016)... SAN FRANCISCO , May 27, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, Neurology and ... Commissiong will be presenting at two upcoming investor conferences: ... Conference Center, 730 Third Avenue, New York City ... at 3:00pm Marcum MicroCap Conference   ...
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
Breaking Medicine Technology: